Avidity Biosciences, Inc.

Avidity Biosciences, Inc.

Biotechnology

San Diego, California 15,461 followers

At Avidity, we are developing a new class of oligonucleotide-based therapies.

About us

DELIVERING ON OUR VISION Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people. Through this platform, we are pleased to share our ideas and company progress as we advance our science and overall mission to deliver breakthrough therapies to patients.

Website
http://www.aviditybiosciences.com
Industry
Biotechnology
Company size
51-200 employees
Headquarters
San Diego, California
Type
Public Company
Founded
2013
Specialties
drug discovery and development, nucleic acids, RNA, and rare disease

Locations

  • Primary

    10578 Science Center Dr

    Suite 125

    San Diego, California 92121, US

    Get directions

Employees at Avidity Biosciences, Inc.

Updates

  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    We are very pleased to share positive data from our Phase 1/2 EXPLORE44™ trial for people living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (#DMD44). DMD44 is a devastating rare hereditary disease causing progressive, debilitating muscle damage and significantly reduced life expectancy. This is the first AOC in development from our DMD franchise and with this data, we are also advancing additional exon-skipping DMD candidates. These data represent another important milestone in our efforts to advance meaningful therapies for people living with rare neuromuscular diseases, including DMD44, and further reinforce the promise of our AOC platform to profoundly improve people’s lives. We are grateful to the #DMD community for their time, commitment and continued contributions as we advance a potential new treatment for DMD44.  Today at 8:00am ET, Avidity’s management team will be hosting an investor & analyst event highlighting the data from the EXPLORE44 trial. Visit our website to register for the event here: https://lnkd.in/e5AHJiGT. For more information on our data from EXPLORE44, read our press release: https://lnkd.in/enSVXcPT

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    As we celebrate #RNADay today, we want to recognize the scientists and researchers who continue to drive innovation in the RNA field. As a leader in RNA-based therapeutics, we are proud to leverage our proprietary Antibody Oligonucleotide Conjugates (AOC) platform which combines the targeting precision of antibodies with the therapeutic potential of oligonucleotides to advance our clinical development programs for three rare muscle diseases: #DM1, #FSHD, and #DMD. Over the last year, we have shared exciting data across all three clinical programs, reaffirming the potential of our AOC platform to profoundly improve people’s lives. Today we want to recognize and celebrate the important efforts of our #BeAVID team as we work to realize our vision to revolutionize RNA therapeutics and bring treatments to patients as quickly as possible. Learn more about our AOC platform and our work in the RNA field in a recent Drug Development & Delivery article, featuring our Distinguished Scientist and Strategic Leader, Art Levin, PhD. Read the article: https://lnkd.in/eWBrJiAM

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    Meet Jordan Miles, our summer #SupplyChain intern from Project Onramp. Jordan is a current student at the University of San Diego pursuing a degree in industrial and systems engineering. He values Avidity’s commitment to providing insights into the different functions and roles within the biopharmaceutical industry and looks forward to learning more about the #biotech industry's supply chain dynamics. Learn more about our work at Avidity at https://lnkd.in/dH-56XKM

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    In a special edition of Newsweek's “The New Era of Life Sciences 2024” Avidity's President and Chief Executive Officer Sarah Boyce highlights our work in pioneering RNA therapeutics using Antibody Oligonucleotide Conjugates (AOCs™), to target a wide range of rare diseases including #DM1, #FSHD, and #DMD44. “Looking ahead, I envision Avidity as a transformative force in the lives of people affected by rare and previously untreatable diseases. Our goal is to profoundly impact healthcare and patient lives, marking a new era in the treatment of rare diseases.” - President and Chief Executive Officer Sarah Boyce Read the full interview: https://lnkd.in/e_4nbXaM

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    Receiving a diagnosis of #Duchenne muscular dystrophy (#DMD) can be incredibly overwhelming, impacting not only the patient, but also their entire support network – parents, siblings, family members, and friends. DMD is a rare, genetic condition that is characterized by progressive muscle damage and weakness, affecting 1 in 3,500 to 5,000 boys. CureDuchenne provides a variety of resources for newly diagnosed individuals and their families, including a virtual caregiver course and education program, to empower them with the knowledge to navigate diagnosis with resilience and strength. We are grateful to partner with CureDuchenne throughout the year to support initiatives that make a difference in the lives of everyone affected by Duchenne. Learn more: https://lnkd.in/e2uuBPc9

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    Meet Michael Delitala, our Quality Systems & Compliance lead. Michael spearheads continuous improvement initiatives within Avidity’s quality management system. He plays a critical role in defining and executing comprehensive quality management reviews, ensuring our processes align with regulatory standards and promoting operational excellence across our organization. Michael's dedication to regulatory readiness strengthens our commitment to delivering transformational therapies to patients worldwide. Learn more about our work at Avidity at https://lnkd.in/dH-56XKM

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    We are proud to serve on the Global Task Force of Project Mercury, an open collaboration spearheaded by the FSHD Society. This initiative unites global stakeholders to overcome challenges in delivering effective #FSHD therapies to patients. Recently, Josie Godfrey, a patient advocate and consultant for Project Mercury, and Amanda Hill, Director of Clinical Research at the FSHD Society, hosted a webcast sharing updates from Project Mercury and plans to build a global cohort of 10,000 clinical-trial ready patients by 2025. With our recently reported positive initial data from the Phase 1/2 FORTITUDE™ trial in people living with facioscapulohumeral muscular dystrophy (FSHD), we are excited about the potential to advance FSHD treatment options and improve lives worldwide. Watch the webcast here https://lnkd.in/e7yzaXqw and learn more about the Phase 1/2 FORTITUDE™ trial at https://lnkd.in/dH-56XKM

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    In the June issue of Drug Development & Delivery, Avidity’s Distinguished Scientist and Strategic Leader, Art Levin, PhD, discusses how we are developing a new class of RNA therapeutics with the potential to precisely target and modify the underlying genetic drivers of diseases. At Avidity, we’re leveraging our proprietary AOC platform to advance our clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (#DM1), facioscapulohumeral muscular dystrophy (#FSHD), and Duchenne muscular dystrophy (#DMD). In the last year, we have shared exciting data from all three programs, further reinforcing the promise of our AOC platform to profoundly improve people's lives by revolutionizing the delivery of RNA therapeutics. Read the full article: https://lnkd.in/eq-MCCVf

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    Meet Xabier Rivera, our summer #IT intern. Xabier recently graduated with a degree in criminal justice from San Diego State University and is working to pursue a master’s degree in cybersecurity engineering in the fall at the University of San Diego. During a career fair at SDSU, Xabier was drawn to our mission to profoundly improve the lives of people with #rarediseases due to his personal experience in the community. His belief in the transformative impact of R&D for patients was strengthened by his mother's diagnosis with a rare birth disorder. We’re excited to welcome Xabier to our team this summer and look forward to having other talented students join our internship program, where they can apply their academic knowledge to real-world settings while demonstrating our #BeAVID values. Learn more about our work at Avidity at https://lnkd.in/dH-56XKM

    • No alternative text description for this image
  • View organization page for Avidity Biosciences, Inc., graphic

    15,461 followers

    Last month we wrapped up the 2024 MDF Regional Conference Series after partnering with Myotonic Dystrophy Foundation for six impactful one-day events which provided an opportunity to connect with local myotonic dystrophy communities, patients, caregivers and advocates nationwide. At Avidity, patient and caregiver perspectives drive our research and development efforts, inspiring us as we stay committed to our mission to improving the lives of people affected by serious diseases. With the initiation of the global pivotal HARBOR study, we remain steadfast in our commitment to making a meaningful difference in the lives of people living with #DM1. Thank you to the MDF for organizing this series, the participants, and all who helped make these events so successful. Learn more about our DM1 clinical program: https://lnkd.in/dH-56XKM

Similar pages

Browse jobs

Funding

Avidity Biosciences, Inc. 8 total rounds

Last Round

Post IPO equity

US$ 461.0M

See more info on crunchbase